

Lexaria Bioscience Corp.  
Form 8-K  
March 21, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **March 20, 2019**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

|  |   |   |
|--|---|---|
| <b>Nevada</b><br>(State or other jurisdiction<br>of incorporation) | <b>000-52138</b><br>(Commission<br>File Number) | <b>20-2000871</b><br>(IRS Employer<br>Identification No.) |
|--|---|---|

**100 – 740 McCurdy Road, Kelowna, BC**  
**Canada**  
(Address of principal executive offices)

**V1X 2P7**  
(Zip Code)

Registrant's telephone number, including area code **(250) 765-6424**

**N/A**  
(Former name or former address, if changed since last report.)

Edgar Filing: Lexaria Bioscience Corp. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

### **Item 1.02 Termination of a Material Definitive Agreement**

On March 20, 2019 Lexaria BioScience Corp. (“Lexaria”) announced that the Definitive License Agreement entered into between Lexaria’s subsidiary, Lexaria CanPharm ULC, and NeutriSci International Inc. (“NeutriSci”), as originally announced on February 26, 2018, whereby NeutriSci was granted a license to Lexaria’s DehydraTECH<sup>™</sup>, to produce tablets incorporating less than 0.3% tetrahydrocannabinol, has been terminated effective March 15, 2019.

### **Item 8.01 Other Events**

On March 20, 2019 Lexaria announced the commencement its largest cannabinoid research program which will also include testing of Lexaria-designed nanotech enhancements to its current technology.

### **Item 9.01 Financial Statements and Exhibits**

99.1 Press Release dated March 20, 2019

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

*/s/ Chris Bunka*

**Chris Bunka**

CEO, Principal Executive Officer

Date: March 21, 2019